Össur hf
Market Cap
US$3.0b
Last Updated
2020/09/30 00:10 UTC
Data Sources
Company Financials +
Executive Summary
Össur hf., together with its subsidiaries, designs, develops, produces, and sells non-invasive orthopedic products in Europe, the Middle-East, Africa, the Americas, and the Asia-Pacific. More Details
Rewards
Risk Analysis
Snowflake Analysis
Moderate growth potential with mediocre balance sheet.
Similar Companies
Share Price & News
How has Össur hf's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: OSSF.F has not had significant price volatility in the past 3 months.
Market Performance
7 Day Return
0%
OSSF.F
0.6%
US Medical Equipment
1.3%
US Market
1 Year Return
-9.3%
OSSF.F
17.1%
US Medical Equipment
15.8%
US Market
Return vs Industry: OSSF.F underperformed the US Medical Equipment industry which returned 17.1% over the past year.
Return vs Market: OSSF.F underperformed the US Market which returned 15.8% over the past year.
Shareholder returns
| OSSF.F | Industry | Market | |
|---|---|---|---|
| 7 Day | 0% | 0.6% | 1.3% |
| 30 Day | 0% | -2.4% | -4.1% |
| 90 Day | -0.7% | 10.6% | 8.4% |
| 1 Year | -9.3%-9.3% | 18.1%17.1% | 18.4%15.8% |
| 3 Year | 55.7%55.7% | 70.9%66.5% | 38.2%29.0% |
| 5 Year | n/a | 144.0%125.3% | 84.9%64.0% |
Price Volatility Vs. Market
How volatile is Össur hf's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Valuation
Is Össur hf undervalued compared to its fair value and its price relative to the market?
164.39x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: OSSF.F ($6.85) is trading above our estimate of fair value ($3.36)
Significantly Below Fair Value: OSSF.F is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: OSSF.F is poor value based on its PE Ratio (164.4x) compared to the US Medical Equipment industry average (49.6x).
PE vs Market: OSSF.F is poor value based on its PE Ratio (164.4x) compared to the US market (18x).
Price to Earnings Growth Ratio
PEG Ratio: OSSF.F is poor value based on its PEG Ratio (3.9x)
Price to Book Ratio
PB vs Industry: OSSF.F is overvalued based on its PB Ratio (5.7x) compared to the US Medical Equipment industry average (4x).
Next Steps
Future Growth
How is Össur hf forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
42.2%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: OSSF.F's forecast earnings growth (42.2% per year) is above the savings rate (2.2%).
Earnings vs Market: OSSF.F's earnings (42.2% per year) are forecast to grow faster than the US market (22.8% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: OSSF.F's revenue (7% per year) is forecast to grow slower than the US market (9.9% per year).
High Growth Revenue: OSSF.F's revenue (7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: OSSF.F's Return on Equity is forecast to be low in 3 years time (13.3%).
Next Steps
Past Performance
How has Össur hf performed over the past 5 years?
5.3%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: OSSF.F has a large one-off loss of $25.5M impacting its June 30 2020 financial results.
Growing Profit Margin: OSSF.F's current net profit margins (3%) are lower than last year (13%).
Past Earnings Growth Analysis
Earnings Trend: OSSF.F's earnings have grown by 5.3% per year over the past 5 years.
Accelerating Growth: OSSF.F's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: OSSF.F had negative earnings growth (-77.3%) over the past year, making it difficult to compare to the Medical Equipment industry average (1.8%).
Return on Equity
High ROE: OSSF.F's Return on Equity (4%) is considered low.
Next Steps
Financial Health
How is Össur hf's financial position?
Financial Position Analysis
Short Term Liabilities: OSSF.F's short term assets ($393.0M) exceed its short term liabilities ($149.4M).
Long Term Liabilities: OSSF.F's short term assets ($393.0M) do not cover its long term liabilities ($496.5M).
Debt to Equity History and Analysis
Debt Level: OSSF.F's debt to equity ratio (69.6%) is considered high.
Reducing Debt: OSSF.F's debt to equity ratio has increased from 24.9% to 69.6% over the past 5 years.
Debt Coverage: OSSF.F's debt is well covered by operating cash flow (29.3%).
Interest Coverage: OSSF.F's interest payments on its debt are well covered by EBIT (8.1x coverage).
Balance Sheet
Next Steps
Dividend
What is Össur hf current dividend yield, its reliability and sustainability?
0.30%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: OSSF.F's dividend (0.3%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.71%).
High Dividend: OSSF.F's dividend (0.3%) is low compared to the top 25% of dividend payers in the US market (4.83%).
Stability and Growth of Payments
Stable Dividend: OSSF.F is not paying a notable dividend for the US market, therefore no need to check if payments are stable.
Growing Dividend: OSSF.F is not paying a notable dividend for the US market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: OSSF.F is not paying a notable dividend for the US market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of OSSF.F's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
4.5yrs
Average management tenure
CEO
Jón Sigurdsson (64 yo)
24.67yrs
Tenure
US$1,694,000
Compensation
Mr. Jón Sigurdsson has been the Chief Executive Officer and President of Gibaud SAS since 1996. Mr. Sigurdsson has been Senior Vice President of Procurement at Promens Canada Inc. and Promens hf. since Jul ...
CEO Compensation Analysis
Compensation vs Market: Jón's total compensation ($USD1.69M) is below average for companies of similar size in the US market ($USD5.74M).
Compensation vs Earnings: Jón's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & President | 24.67yrs | US$1.69m | 0.12% $ 3.8m | |
| no data | US$25.00k | no data | ||
| Chief Financial Officer | 7.33yrs | US$221.00k | 0.0059% $ 178.6k | |
| Executive Vice President of Manufacturing & Operations | no data | US$444.00k | 0.20% $ 5.9m | |
| Investor Relations Manager | no data | no data | no data | |
| Compliance Officer | 18.67yrs | no data | no data | |
| Executive Vice President of Sales & Marketing | 4.5yrs | US$600.00k | 0.0023% $ 68.1k | |
| Executive Vice President of Human Resources & Corporate Strategy | no data | US$242.00k | 0.0039% $ 116.5k | |
| Executive Vice President of Clinics | 2.83yrs | no data | 0.010% $ 305.4k | |
| Executive Vice President of Research & Development | 0.75yr | no data | 0.00044% $ 13.3k | |
| Consultant | 2.83yrs | US$422.00k | no data |
4.5yrs
Average Tenure
60yo
Average Age
Experienced Management: OSSF.F's management team is considered experienced (4.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Board | 14.67yrs | US$97.00k | 0.048% $ 1.5m | |
| Vice Chairman | 8.5yrs | US$58.00k | no data | |
| Independent Director | 12.67yrs | US$39.00k | no data | |
| Independent Director | 7.5yrs | US$39.00k | 0.0062% $ 187.9k | |
| Director | 11.67yrs | US$39.00k | no data |
11.7yrs
Average Tenure
63yo
Average Age
Experienced Board: OSSF.F's board of directors are seasoned and experienced ( 11.7 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Össur hf.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Össur hf.
- Ticker: OSSF.F
- Exchange: OTCPK
- Founded: 1971
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: kr.19.102b
- Listing Market Cap: kr.3.011b
- Shares outstanding: 421.67m
- Website: https://www.ossur.com
Number of Employees
Location
- Össur hf.
- Grjothals 1-5
- Reykjavik
- 110
- Iceland
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| 0FIW | LSE (London Stock Exchange) | Yes | Common Stock | GB | DKK | Oct 1999 |
| OSSR | CPSE (OMX Nordic Exchange Copenhagen) | Yes | Common Stock | DK | DKK | Oct 1999 |
| OSSRC | BATS-CHIXE (BATS 'Chi-X Europe') | Yes | Common Stock | GB | DKK | Oct 1999 |
| OSSF.F | OTCPK (Pink Sheets LLC) | Yes | Common Stock | US | USD | Oct 1999 |
| OSSU.Y | OTCPK (Pink Sheets LLC) | SPONSORED ADR | US | USD | Dec 2011 |
Biography
Össur hf., together with its subsidiaries, designs, develops, produces, and sells non-invasive orthopedic products in Europe, the Middle-East, Africa, the Americas, and the Asia-Pacific. The company’s pros ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/09/30 00:10 |
| End of Day Share Price | 2020/08/14 00:00 |
| Earnings | 2020/06/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.